Vassiliki Papadimitrakopoulou

Trials

Studies that name Vassiliki Papadimitrakopoulou as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:12 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03377556 · Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

  SWOG Cancer Research Network · completed · ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation · principal investigator
• Ph2
  NCT03373760 · Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

  SWOG Cancer Research Network · completed · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 · principal investigator
• Ph2/Ph3
  NCT02965378 · Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  SWOG Cancer Research Network · completed · FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification · principal investigator
• Ph2/Ph3
  NCT02926638 · Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  SWOG Cancer Research Network · terminated · MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 · principal investigator
• Ph3
  NCT02785952 · Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  SWOG Cancer Research Network · active not recruiting · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 · principal investigator
• Ph2
  NCT02785913 · Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  SWOG Cancer Research Network · completed · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma · principal investigator
• Ph2/Ph3
  NCT02785939 · Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  SWOG Cancer Research Network · completed · CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification · principal investigator
• Ph2/Ph3
  NCT02766335 · Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  SWOG Cancer Research Network · completed · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 · principal investigator
• N/A
  NCT02154490 · Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  SWOG Cancer Research Network · completed · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 · principal investigator
• Ph2
  NCT00507767 · Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

  National Cancer Institute (NCI) · completed · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer · principal investigator
• Ph3
  NCT00402779 · Erlotinib Prevention of Oral Cancer (EPOC)

  M.D. Anderson Cancer Center · completed · Oral Cancer · principal investigator
• Ph2
  NCT00290537 · Phase II Study of ZD6474 in Advanced NSCLC

  M.D. Anderson Cancer Center · terminated · Lung Cancer · principal investigator
• Ph1
  NCT00005973 · BMS-214662 in Treating Patients With Solid Tumors

  National Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2015 to 2026
  Named on NCT03377556, NCT03373760, NCT02965378, NCT02926638, NCT02785952, NCT02785939, NCT02766335, NCT02154490
• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2015 to 2026
  Named on NCT00507767
• P01CA106451
  RePORTER returned no project for this number; it is shown as the registry gives it.
  Named on NCT00402779
• U01CA062461
  RePORTER returned no project for this number; it is shown as the registry gives it.
  Named on NCT00005973